Clinical Application of the Adenosine Triphosphate-based Response Assay in Intravesical Chemotherapy for Superficial Bladder Cancer

  • Ge, Wen-Qing (Department of Urinary Surgery, The First Affiliated hospital of Soochow University) ;
  • Pu, Jin-Xian (Department of Urinary Surgery, The First Affiliated hospital of Soochow University) ;
  • Zheng, Shi-Ying (Department of Thoracic Cardiac Surgery, The First Affiliated hospital of Soochow University)
  • Published : 2012.02.29


Objective: To investigate correlations between adenosine triphosphate chemotherapy response assay (ATP-CRA) and clinical outcomes after ATP-CRA-based chemotherapy for drug selection in patients receiving intravesical chemotherapy to prevent recurrence of superficial bladder cancer after surgery. Methods: The chemosensitivities of 12 anticancer drugs were evaluated, including 5-Fu ADM, and EPI, using ATP-CRA and primary tumor cell culture in 54 patients. In addition, a further 58 patients were treated according to clinical experience. Differences in post-chemotherapeutical effects between drug sensitivity assay and experience groups were compared. Results: The evaluable rate of the test was 96.3%, the clinical effective rate was 80.8%, the sensitivity rate was 97.6% (41/42), the specificity was 20%, the total predicting accuracy was 74.3%, the positive predictive value was 83.7% (41/49), the negative predictive value was 66.7% (2/3); in the drug sensitivity test group, the clinical effective rate was 80.8%, the experience group response rate was 63.8%, with a significant difference in clinical effects between the ATP-based sensitivity and experience groups (${\chi}^2$=7.0153, P<0.01). Conclusion: ATP-CRA is a stable, accurate and potentially practical chemosensitivity test providing a predictor of chemotherapeutic response in patients with superficial bladder cancer.


Adenosine triphosphate;chemotherapy response assay;superficial bladder cancer


  1. Cree IA, Andreotti PE (1997). Measurement of cytotoxicity by ATP based luminescence assay in primary cell cultures and cell lines. Toxicol In Vitro, 11, 553-6.
  2. Cree IA, Kurbacher CM (1997). Individualizing chemotherapy for solid tumors-is there any alternative? Anticancer Drugs, 8, 541-8.
  3. Cree IA, Kurbacher CM, Lamont A, et a1 (2007). A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs, 18, 1093-101.
  4. Ekwall B, Sussman N (2000). ATP is the most accurate endpoint for in vitro predicting of cytotoxicity. ATLA, 28, 201-34.
  5. Garcia O, Massieu L (2003). Glutamate uptake inhibitor L-Transpyrrolidine 2, 4-dicarboxylate becomes neurotoxic in the presence of subthreshold concentrations of mitochondrial toxin 3-nitropropionate: involvement of mitochondrial reducing activity and ATP production. J Neurosci Res, 74, 956-66.
  6. Gasion JP, Cruz JF (2006). Improving Efficacy of Intravesical Chemotherapy. European Urology, 50, 225-34.
  7. Huh JW, Park YA, Lee KY, et al (2009). Heterogeneity of adenosine triphosphate-based chemotherapy response assay in colorectal cancer-secondary publication. Yonsei Med, 50, 697-703.
  8. Jichlinski P, Guillou L, Karlsen SJ, et al (2003). Hexylaminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--A multicenter study. J Urol, 170, 226-9.
  9. Kangas L, Gronroos M, Nieminen AL (1984). Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. Med Biol, 62, 338-43.
  10. Kornmann M, Beger HG, Link KH (2003). Chemosensitivity testing and test-directed chemotherapy in human pancreatic cancer. Recent Results Cancer Res, 161, 180-95.
  11. Kurbacher CM, Grecu OM, Stier U, et al (2003). ATP chemosensitivity testing in ovarian and breast cancer:early clinical trials. Recent Results Cancer Res, 161, 221-30.
  12. Moon YW, Choi SH, Kim YT, et al (2007). Adenosine triphosphate-based chemotherapy response assay (ATPCRA)- guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer. Cancer, 109, 1829.
  13. Mueller H, Kassack MU, Wiese M (2004). Comparison of the usefulness of the MTT,ATP and calcein assays to predict the potency of cytotoxic agents in various human cancer cell lines. J Biomol Screen, 9, 506-15.
  14. O'Meara AT, Sevin BU (2001). Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer. Gynecol Oncol, 83, 334-421.
  15. Riedl CR, Daniltchenko D, Koenig F, et al (2001). Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrencen rate in superficial bladder cancer. J Urol, 165, 1121-3.
  16. Schmittgen TD, Au JLS, Wientjes G, et a1 (1991). Cultured human bladder tumors for pharmacodynamic studies. Urology, 145, 203-7.
  17. Serretta V, Galuffo A, Pavone C, et al (2005). Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions. Urology, 65, 65-9.
  18. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al (2006). Predicting recurrence and progression in individual patients with stage Ta T1bladder cancer using EORTC risk tables:a combined analysis of 2596 patients from seven EORTC trial. Eur Urol, 49, 466-77.
  19. Ulukaya E, Ozdikicioglu F, Oral AY, et al (2008). The MTT assay yields a relatively lower result of growth inhibition than the ATP assay depending on the chemotherapeutic drugs tested. Toxicol In Vitro, 22, 232-9.
  20. Yamaue H, Tanimura H, Tsunoda T, et al (1991). Chemosensitivity testing with highly purified fresh human tumour cells with the MTT colorimetric assay. Eur J Cancer, 27, 1258-63.

Cited by

  1. Sulforaphane Inhibits the Proliferation of the BIU87 Bladder Cancer Cell Line via IGFBP-3 Elevation vol.15, pp.4, 2014,